SIU 2017 Prostate Cancer
SIU 2017: Role of Cytoreductive Surgery in CRPC
SIU 2017: Advances in Imaging in CRPC: New Ligands for Pet Imaging
SIU 2017: Optimal Sequencing and Monitoring of Androgen Receptor (AR) Pathway Inhibitors in mCRPC
SIU 2017: Mechanisms of Treatment Induced Resistance
SIU 2017: Towards Precision Medicine in Advanced Prostate Cancer
SIU 2017: The Utility of Subsequent Prostate Biopsies for the Active Surveillance of Prostate Cancer when Genomics and MRI Are Negative
As an introduction, Dr. Cooperberg noted that AS has finally been recognized as the standard of care for low-risk PCa, as opposed to an option. However, those same guidelines do NOT mention high-risk groups, such as African-Americans, younger men, and high volume disease. While AS currenty entails an initial biopsy and a confirmatory biopsy at 6-12 months, following by surveillance regimens that vary significantly, most surveillance protocols still call for repeat biopsies during follow-up. However, along this management course, there are numerous new genomic tests that can be utilized to alter risk level as well as mpMRI. How do these tests affect decision making and can they replace biopsy?